Precision before scale
Begin with the molecular context of the individual tumor, then build systems that can scale without losing it.
Start a conversation About MendCipher
Built for the
one-of-one biology of cancer.
Our mission is to make personalized therapeutic design more systematic, interpretable, and testable.
THE BEGINNING01
Why we exist
Population averages built modern oncology.
The next layer is individual.
Therapeutic development often begins with what is common across many patients. That approach remains essential—but each tumor also carries a distinct, evolving molecular context.
MendCipher Bio was founded to explore a complementary model: begin with the individual tumor, use computation to narrow the design space, and move promising mRNA candidates toward rigorous experimental validation.
Who we are
A new company
for a converging field.
MendCipher Bio is an early-stage, founder-led biotechnology company working where computational biology, mRNA engineering, and translational oncology meet.
01 Computational biology02 RNA design & engineering03 Translational oncology04 Experimental validation
Current stage: developing the core platform and assembling the scientific relationships needed to test it well.
How we work
Ambition,
with discipline.
Our operating principles are designed for the long work of turning a computational hypothesis into trustworthy biological evidence.
Evidence over eloquence
A compelling model output is still only a hypothesis. Measured biology has the final word.
Humans remain accountable
Scientists and domain experts own consequential decisions; AI supports their work.
Design with translation in mind
Feasibility, safety, and manufacturability belong in the design conversation from the beginning.
RESEARCH STATUS / JUL 2026Early by design.
Early by design.
Clear about the work ahead.
MendCipher's platform and programs are under development. We are not offering clinical care, making treatment recommendations, or claiming therapeutic efficacy.
Build with us